[ad_1]
Vaccine Rage!
“The Federal Chancellery has just announced that the promised deliveries of Moderna vaccines will now also be reduced,” Hamburg’s first mayor Peter Tschentscher (SPD) tweeted on Saturday.
According to information from BILD, Biontech will deliver more vaccines than previously known.
► In the fifth calendar week, Biontech delivers 56,000 more cans than planned.
► In the sixth calendar week (second week of February) there is a gap in Moderna: 43,200 fewer doses of vaccine!
► In the seventh calendar week there are 158,000 more cans of Biontech than anticipated.
So there is more vaccine than was initially announced. But of course, that is far from enough.
However, the Health Ministry said that Moderna’s reduction in vaccine deliveries in Germany will be more than offset by excess deliveries from Biontech and AstraZeneca. AstraZeneca announced that it would ship 600,000 cans on February 7 and another 926,400 ten days later.
So far, the EU Commission has signed contracts with six vaccine manufacturers on behalf of the 27 states, securing around 2.3 billion doses of various products. More to follow:
► The preparation of the Mainz company Biontech and the US pharmaceutical giant Pfizer was the first corona vaccine approved in the EU. On December 21, 2020, the EU Commission gave the green light.
Germany has insured around 94 million cans.
► The second drug approved in the EU followed on January 6 with the vaccine Modern American manufacturer. Germany has ordered 50 million cans so far, and at 94 percent, Moderna’s product is as effective as Biontech’s.
► AstraZeneca: At 70 percent effective, the British-Swedish manufacturer’s vaccine, which received EU approval on Friday, is somewhat less reliable. Brussels had ordered 80 million doses of vaccines at the end of March.
The fact that it is now less is causing a dispute between Brussels and the manufacturer. The federal government had estimated about 56 million cans.
► Curevac: The Tübingen-based biotech company is investigating a drug for which the approval-relevant phase III clinical trial began in December. Curevac, which cooperates with the pharmaceutical company Bayer, expects results by the end of March.
The federal government has ordered up to 73 million doses of the vaccine.
► The American manufacturer Johnson and Johnson the decisive phase of clinical trials started in September 2020. The special feature of the agent is that only one dose should provide sufficient protection. Germany will receive 37.25 million cans.
The time when the vaccine could be approved in the EU is still open.
► Sanofi / GSK: The EU Commission had already signed a contract with the pharmaceutical companies of France and Great Britain in September 2020. But there were setbacks in the development of the vaccine.
Manufacturers now expect the earliest possible availability in the fourth quarter of 2021. If the agent is approved, EU states could buy up to 300 million cans.
► Valneva: In mid-January, the EU Commission concluded exploratory talks with the French biotech company. The planned contract provides for the purchase of up to 60 million cans. According to the EU Commission, Valneva is developing a “classic” vaccine with inactivated viruses.
► Novavax: At 90 percent effective, the candidate vaccine from this American manufacturer also gives hope. The US pharmaceutical Baxter announced in mid-January that the Novavax vaccine, which has not yet been approved, would be manufactured at the Baxter branch in Halle (North Rhine-Westphalia), among other places. Biontech and Pfizer also want to produce their vaccine in Halle in the future.
